BioPharmSignal logoBioPharmSignal

Biotech News

Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Oculis (OCS)OculisCompany update

Latest findings from the DME AWARE Delphi Study on unmet needs in diabetic macular edema (DME) management highlighting the need for non-invasive therapeutic options to be presented by Baruch Kuppermann, M.D., Ph.D. New post-hoc analysis of OCT scans on GCIPL and analysis of responders with

Related news

OCSOculis2026-05-05 08:00 EST

Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting

OCSOculis2026-04-20 08:00 EST

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

OKYOOKYO Pharma2026-04-29 11:00 EST

OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

OKYOOKYO Pharma2026-07-21 13:00 EST

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

SGHTSight Sciences2026-04-29 20:05 EST

Sight Sciences to Present at Two Upcoming Investor Conferences

MGTXMeiraGTx2026-04-14 12:30 EST

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

OCULOcular Therapeutix2026-04-01 11:00 EST

Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

HROWHarrow, Inc.2026-07-20 11:00 EST

Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

LCTXLineage Cell Therapeutics2026-07-06 12:00 EST

Lineage Cell Therapeutics to Present at B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

SGHTSight Sciences2026-04-01 20:05 EST

Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-08-06 20:05 EST

Oculis Reports Q2 2026 Financial Results and Provides Company Update

OCSOculis2026-08-03 08:00 EST

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

OCSOculis2026-07-08 20:05 EST

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

OCSOculis2026-07-02 08:00 EST

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference

Stock data

Close
12.38 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States